Plain-English translation of NCT06001086 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications used together—Disitamb Vedotin and pyrotinib—can effectively treat early-stage HER2-positive breast cancer in patients who have never received cancer treatment before. HER2-positive breast cancer means the cancer cells have high levels of a protein called HER2. The study wants to see how well this medication combination works and how safe it is.
HER2-positive breast cancer is an aggressive type that needs targeted treatment. This trial is testing whether combining these two medications might be more effective than existing treatments in stopping the cancer from returning.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive one medication (Disitamb Vedotin) by IV infusion on specific days, and take the other medication (pyrotinib) as a daily oral pill. Treatment happens in cycles, with each cycle lasting 28 days. You will have regular visits to the hospital or clinic for infusions, blood tests, and imaging scans to monitor how well the treatment is working and check for side effects. The study expects to enroll about 70 patients total.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Collaborators
First Affiliated Hospital of Wenzhou Medical University
Enrollment target
~70 participants
Started
November 2023
Primary completion
August 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wei Li, Ph.D
The First Affiliated Hospital with Nanjing Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.